NCT02370563View on ClinicalTrials.gov

PET Imaging of Intracranial Cancers With 18F-FSPG

PHASE1TerminatedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions
Brain Cancer
Interventions
DRUG

18F-FSPG

18F-FSPG is a novel F18-labelled, radiopharmaceutical agent for PET imaging. It is administered intravenously at a dose of 300 MBq (8.1mCi ± 10%).

Trial Locations (1)

94305

Stanford University Medical Center, Stanford

Sponsors
All Listed Sponsors
lead

Life Molecular Imaging SA

INDUSTRY